<DOC>
	<DOC>NCT00615134</DOC>
	<brief_summary>This 2 arm study will assess the efficacy and safety of a new regimen of Fuzeon + optimized background antiretroviral treatment, in Fuzeon-naive HIV-1 infected patients with virological failure. Eligible patients will be randomized to recei ve either new optimized treatment alone, or optimized treatment + Fuzeon 90mg s. c. twice daily, to determine the effect of 3 month induction with Fuzeon.It will be possible for a patient to receive several additional 3 month periods with F uzeon, in the case of new virological failure. The anticipated time on study tre atment is 3-12 months, and the target sample size is &lt;100 individuals.</brief_summary>
	<brief_title>INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Enfuvirtide</mesh_term>
	<criteria>adult patients, &gt;=18 years of age; HIV1 infection, with virologic failure; on same stable HAART for &gt;4 weeks, with viral load &gt;1000 RNA copies/mL; Fuzeonnaive. coinfection with HIV2; active opportunistic infection in 4 weeks prior to screening; cirrhosis or severe liver failure; severe renal disease.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>treatment experienced</keyword>
</DOC>